Trevi Therapeutics, Inc. Repayments of Long-Term Debt
Trevi Therapeutics, Inc. (TRVI) reported Repayments of Long-Term Debt of $9.41 million for the 9-month period ending 2023-09-30, per its 10-Q filed 2024-11-06.
Financial Statements › Cash Flow › Financing Activities
us-gaap:RepaymentsOfLongTermDebt · last filed 2024-11-06
- Trevi Therapeutics, Inc. repayments of long-term debt for the quarter ending 2023-09-30 was $0.00, a 100.00% decline year-over-year.
- Trevi Therapeutics, Inc. repayments of long-term debt for the quarter ending 2023-06-30 was $7.66M, a 337.66% increase year-over-year.
- Trevi Therapeutics, Inc. repayments of long-term debt for the quarter ending 2023-03-31 was $1.75M, a 200.17% increase year-over-year.
- Trevi Therapeutics, Inc. repayments of long-term debt for the quarter ending 2022-12-31 was $1.75M.
- Trevi Therapeutics, Inc. repayments of long-term debt for fiscal 2022 was $5.83M.
- Trevi Therapeutics, Inc. repayments of long-term debt for fiscal 2018 was $4.81M.
| Period end | Repayments of Long-term Debt 3 month | Repayments of Long-term Debt 6 month | Repayments of Long-term Debt 9 month | Repayments of Long-term Debt 12 month |
|---|---|---|---|---|
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $7.66M derived: sum of 2 quarters · filed 2024-11-06 | $9.41M 10-Q · filed 2024-11-06 | $11.16M derived: sum of 4 quarters · filed 2024-11-06 |
| 2023-06-30 | $7.66M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $9.41M 10-Q · filed 2024-08-08 | $11.16M derived: sum of 3 quarters · filed 2024-08-08 | $12.91M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | $1.75M 10-Q · filed 2024-05-07 | $3.50M derived: sum of 2 quarters · filed 2024-05-07 | $5.25M derived: sum of 3 quarters · filed 2024-05-07 | $7.00M derived: sum of 4 quarters · filed 2024-05-07 |
| 2022-12-31 | $1.75M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-16 | $3.50M derived: sum of 2 quarters · filed 2023-03-16 | $5.25M derived: sum of 3 quarters · filed 2023-03-16 | $5.83M 10-K · filed 2023-03-16 |
| 2022-09-30 | $1.75M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | $3.50M derived: sum of 2 quarters · filed 2022-11-10 | $4.08M 10-Q · filed 2022-11-10 | |
| 2022-06-30 | $1.75M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | $2.33M 10-Q · filed 2022-08-11 | ||
| 2022-03-31 | $583.00K 10-Q · filed 2023-05-11 | |||
| 2018-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-16 | $1.00K derived: sum of 2 quarters · filed 2020-03-16 | $2.75M derived: sum of 3 quarters · filed 2020-03-16 | $4.81M 10-K · filed 2020-03-16 |
| 2018-09-30 | $1.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-14 | $2.75M derived: sum of 2 quarters · filed 2019-11-14 | $4.81M 10-Q · filed 2019-11-14 | |
| 2018-06-30 | $2.75M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-12 | $4.81M 10-Q · filed 2019-08-12 | ||
| 2018-03-31 | $2.06M 10-Q · filed 2019-06-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |